Fulcrum Therapeutics(US:FULC)2026-02-24 12:10Clinical Results - The mean absolute HbF increased by 12.2% at 12 weeks of treatment with pociredir, rising from a baseline of 7.1% to 19.3%[443] - Seven of 12 patients (58%) achieved absolute HbF levels ≥20% at Week 12, which is associated with ~90% of patients experiencing zero VOCs per year[443] - Mean hemoglobin increased by 1.1 g/dL at Week 12, from a baseline of 7.3 g/dL to 8.4 g/dL[443] Financial Performance - The company incurred net losses of $74.9 million and $9.7 million for the years ended December 31, 2025 and 2024, respectively, with an accumulated deficit of $594.3 million as of December 31, 2025[446] - Net loss increased by $65.2 million from $9.7 million in 2024 to $74.9 million in 2025, reflecting higher operating losses[466] - Cash, cash equivalents, and marketable securities totaled $352.3 million as of December 31, 2025, providing liquidity for ongoing operations[473] - Net cash used in operating activities was $60.1 million in 2025, a significant increase from $2.2 million in 2024, primarily due to higher net losses[477] - Net cash provided by financing activities was $168.7 million in 2025, significantly up from $2.7 million in 2024, mainly from a public offering[479] - The company expects to incur substantial operating losses and negative cash flows for the foreseeable future as it continues its research and development activities[480] - The company has not yet commercialized any product candidates and does not expect to generate revenue from product sales for several years[473] Research and Development - Research and development expenses totaled $56.1 million for the year ended December 31, 2025, a decrease from $63.4 million in 2024[459] - Pociredir external expenses increased to $19.99 million in 2025 from $8.58 million in 2024[459] - Research and development expenses decreased by $7.3 million from $63.4 million in 2024 to $56.1 million in 2025, mainly due to reduced external research costs and employee compensation[468] - The company plans to initiate a potential registration-enabling trial for pociredir in the second half of 2026, pending FDA feedback[442] - The company will focus resources on advancing pociredir and core benign hematology programs, discontinuing the program for bone marrow failure syndromes[445] Operating Expenses - Total operating expenses decreased by $17.1 million from $101.9 million in 2024 to $84.8 million in 2025, primarily driven by reductions in research and development and general administrative expenses[466] - General and administrative expenses decreased by $7.8 million from $36.4 million in 2024 to $28.7 million in 2025, attributed to lower employee compensation and professional services costs[469] Revenue and Funding - Collaboration revenue decreased by $80.0 million from $80.0 million in 2024 to $0 in 2025 due to the termination of the Sanofi collaboration agreement[467] - The company expects to finance operations through equity offerings, debt financings, and collaborations, indicating a need for substantial additional funding[447] Accounting and Financial Policies - The company recognizes revenue under ASC 606 when control of promised goods or services is obtained by the customer[490] - The company evaluates accrued research and development expenses based on estimates of services received and efforts expended, with adjustments made as necessary[495] - Stock-based compensation expense is expected to increase in future periods due to unrecognized stock-based compensation and additional awards granted[501] - The company does not currently hedge its foreign currency exchange rate risk, with minimal or no liabilities denominated in foreign currencies as of December 31, 2025[506] - Interest income is sensitive to changes in interest rates, but a 10% change would not materially affect the fair market value of the investment portfolio[505] - The company accounts for uncertain tax positions using a more-likely-than-not threshold, with no uncertain tax positions reported as of each balance sheet date[503] - The company has made an accounting policy election to account for research and development reimbursements as a reduction of expenses[488] - Inflation has not had a material effect on the company's business or financial condition during the years ended December 31, 2025 and 2024[507] - The company uses significant judgment to determine the transaction price and performance obligations in contracts under ASC 606[491]